WHO's December 2025 GLP-1 guideline marks the first global endorsement of pharmacological obesity treatment but its conditional status signals inadequate health system readiness and unresolved equity concerns

On December 1, 2025, WHO issued its first-ever global guideline on GLP-1 medicines for obesity treatment, covering liraglutide, semaglutide, and tirzepatide. Critically, the recommendation is conditional rather than strong. WHO explicitly states the conditional status is driven by: (1) limited data on long-term efficacy and safety, particularly around maintenance and discontinuation; (2) current costs of these medications; (3) inadequate health-system preparedness globally; and (4) potential equity implications. WHO acknowledges that current global access and affordability are 'far below population needs.' This represents a landmark regulatory event—the first time the global health authority has officially endorsed GLP-1 pharmacological treatment for obesity (not just T2DM)—but the conditional framing signals that the evidence base and delivery infrastructure are not yet mature enough for blanket endorsement. The guideline recommends GLP-1s 'may be used' as long-term treatment (continuous use for at least 6 months) based on moderate-certainty evidence, and states they 'should be incorporated into universal health coverage and primary care benefit packages'—but this is not yet reality anywhere in the developing world. The conditional status creates a regulatory signal about evidence maturity and system readiness that differs from a strong endorsement.